145 related articles for article (PubMed ID: 26450349)
1. Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors.
Stanton RA; Nettles JH; Schinazi RF
J Mol Model; 2015 Nov; 21(11):282. PubMed ID: 26450349
[TBL] [Abstract][Full Text] [Related]
2. Identification of Adjacent NNRTI Binding Pocket in Multi-mutated HIV1- RT Enzyme Model: An in silico Study.
Kamil RF; Debnath U; Verma S; Prabhakar YS
Curr HIV Res; 2018; 16(2):121-129. PubMed ID: 29651941
[TBL] [Abstract][Full Text] [Related]
3. Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Chong P; Sebahar P; Youngman M; Garrido D; Zhang H; Stewart EL; Nolte RT; Wang L; Ferris RG; Edelstein M; Weaver K; Mathis A; Peat A
J Med Chem; 2012 Dec; 55(23):10601-9. PubMed ID: 23137340
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
[TBL] [Abstract][Full Text] [Related]
5. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
[TBL] [Abstract][Full Text] [Related]
6. Torsional flexibility of undecorated catechol diether compound as potent NNRTI targeting HIV-1 reverse transcriptase.
Somboon T; Saparpakorn P; Hannongbua S
J Mol Graph Model; 2019 Jan; 86():286-297. PubMed ID: 30445408
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibitor design for HIV-1 reverse transcriptase and integrase enzymes: a molecular docking study.
Ercan S; Şenyiğit B; Şenses Y
J Biomol Struct Dyn; 2020 Feb; 38(2):573-580. PubMed ID: 31787027
[TBL] [Abstract][Full Text] [Related]
8. Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants.
Frey KM
Future Microbiol; 2015; 10(11):1767-72. PubMed ID: 26517310
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).
Vanangamudi M; Poongavanam V; Namasivayam V
Curr Med Chem; 2017 Nov; 24(34):3774-3812. PubMed ID: 28685686
[TBL] [Abstract][Full Text] [Related]
10. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
11. Docking experiments in the flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase.
Titmuss SJ; Keller PA; Griffith R
Bioorg Med Chem; 1999 Jun; 7(6):1163-70. PubMed ID: 10428388
[TBL] [Abstract][Full Text] [Related]
12. Structure-based methods to predict mutational resistance to diarylpyrimidine non-nucleoside reverse transcriptase inhibitors.
Azeem SM; Muwonge AN; Thakkar N; Lam KW; Frey KM
J Mol Graph Model; 2018 Jan; 79():133-139. PubMed ID: 29156381
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
14. Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring.
Barreiro G; Guimarães CR; Tubert-Brohman I; Lyons TM; Tirado-Rives J; Jorgensen WL
J Chem Inf Model; 2007; 47(6):2416-28. PubMed ID: 17949071
[TBL] [Abstract][Full Text] [Related]
15. Molecular insight on the binding of NNRTI to K103N mutated HIV-1 RT: molecular dynamics simulations and dynamic pharmacophore analysis.
Nizami B; Sydow D; Wolber G; Honarparvar B
Mol Biosyst; 2016 Oct; 12(11):3385-3395. PubMed ID: 27722739
[TBL] [Abstract][Full Text] [Related]
16. Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.
Peletskaya EN; Kogon AA; Tuske S; Arnold E; Hughes SH
J Virol; 2004 Apr; 78(7):3387-97. PubMed ID: 15016861
[TBL] [Abstract][Full Text] [Related]
17. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
18. Thumbs down for HIV: domain level rearrangements do occur in the NNRTI-bound HIV-1 reverse transcriptase.
Wright DW; Sadiq SK; De Fabritiis G; Coveney PV
J Am Chem Soc; 2012 Aug; 134(31):12885-8. PubMed ID: 22827470
[TBL] [Abstract][Full Text] [Related]
19. Exploring isoxazole and carboxamide derivatives as potential non-nucleoside reverse transcriptase inhibitors.
Kurup SS; Joshi KA
J Mol Graph Model; 2016 Apr; 65():113-28. PubMed ID: 26973048
[TBL] [Abstract][Full Text] [Related]
20. Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6.
Corona A; Meleddu R; Esposito F; Distinto S; Bianco G; Masaoka T; Maccioni E; Menéndez-Arias L; Alcaro S; Le Grice SF; Tramontano E
PLoS One; 2016; 11(1):e0147225. PubMed ID: 26800261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
